AZD1222
ApprovedTerminated 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
COVID-19, SARS-CoV-2
Conditions
COVID-19, SARS-CoV-2
Trial Timeline
Jan 31, 2022 → Apr 19, 2023
NCT ID
NCT05057897About AZD1222
AZD1222 is a approved stage product being developed by AstraZeneca for COVID-19, SARS-CoV-2. The current trial status is terminated. This product is registered under clinical trial identifier NCT05057897. Target conditions include COVID-19, SARS-CoV-2.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05126992 | Pre-clinical | Completed |
| NCT05057897 | Approved | Terminated |
| NCT04914832 | Approved | Completed |
| NCT04540393 | Phase 3 | Withdrawn |
Competing Products
20 competing products in COVID-19, SARS-CoV-2
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Human COVID-19 immunoglobulin (pH4) for intravenous injection + Placebo | Sinopharm | Phase 2 | 51 |
| Mavrilimumab + Placebos | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| Gimsilumab + Placebo | Roivant Sciences | Phase 2 | 49 |
| Icosapent ethyl | Amarin Corporation | Phase 2 | 44 |
| Bamlanivimab + Placebo + Etesevimab | Eli Lilly | Phase 3 | 77 |
| Infliximab | Celltrion | Phase 2 | 52 |
| CT-P63 and CT-P66 / Placebo | Celltrion | Phase 3 | 77 |
| Enzalutamide Pill | Astellas Pharma | Phase 2 | 52 |
| S-892216 + Placebo | Shionogi | Phase 2 | 52 |
| S-892216 + Carbamazepine | Shionogi | Phase 1 | 33 |
| FOY-305 + Placebo | Ono Pharmaceutical | Phase 3 | 77 |
| Desidustat | Zydus Lifesciences | Phase 2 | 52 |
| LY3819253 + Placebo | Eli Lilly | Phase 1 | 33 |
| Bamlanivimab + Etesevimab + Placebo + VIR-7831 + Bebtelovimab | Eli Lilly | Phase 2 | 52 |
| Bamlanivimab | Eli Lilly | Phase 2 | 52 |
| LY3127804 + Placebo | Eli Lilly | Phase 2 | 52 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 77 |
| Bamlanivimab | Eli Lilly | Pre-clinical | 23 |
| LY3819253 + Placebo + Remdesivir | Eli Lilly | Phase 3 | 77 |
| LY3819253 + LY3832479 + LY3853113 + Placebo | Eli Lilly | Phase 2/3 | 65 |